Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Attard

Showing results (31-40 of 76) with videos related to

Pageof 8
Sort By:
British Journal of Cancer|July 2, 2014
Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trailM Ong, S Carreira, J Goodall, et al.
British Journal of Cancer|November 15, 2007
A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumoursG Attard, J Kitzen, S P Blagden, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 27, 2006
A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumoursA Greystoke, S Blagden, A L Thomas, et al.
British Journal of Cancer|June 29, 2013
Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancerC Pezaro, D Mukherji, N Tunariu, et al.
Clinical Radiology|January 4, 2015
Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancerC Pezaro, A Omlin, R Perez-Lopez, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 28, 2023
The STAMPEDE2 Trial: a Site Survey of Current Patterns of Care, Access to Imaging and Treatment of Metastatic Prostate CancerH Abdel-Aty, L O'Shea, C Amos, et al.
British Journal of Cancer|April 22, 2015
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abirateroneS Salvi, V Casadio, V Conteduca, et al.
European Urology|December 4, 2013
Visceral disease in castration-resistant prostate cancerC Pezaro, A Omlin, D Lorente, et al.
British Journal of Cancer|October 15, 2014
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abirateroneD Lorente, A Omlin, R Ferraldeschi, et al.
British Journal of Cancer|August 10, 2013
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancerA Omlin, C J Pezaro, S Zaidi, et al.
Pageof 8

Showing results (31-40 of 76) with videos related to

Sort By:
Pageof 8
British Journal of Cancer|July 2, 2014
Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trailM Ong, S Carreira, J Goodall, et al.
British Journal of Cancer|November 15, 2007
A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumoursG Attard, J Kitzen, S P Blagden, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 27, 2006
A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumoursA Greystoke, S Blagden, A L Thomas, et al.
British Journal of Cancer|June 29, 2013
Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancerC Pezaro, D Mukherji, N Tunariu, et al.
Clinical Radiology|January 4, 2015
Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancerC Pezaro, A Omlin, R Perez-Lopez, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 28, 2023
The STAMPEDE2 Trial: a Site Survey of Current Patterns of Care, Access to Imaging and Treatment of Metastatic Prostate CancerH Abdel-Aty, L O'Shea, C Amos, et al.
British Journal of Cancer|April 22, 2015
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abirateroneS Salvi, V Casadio, V Conteduca, et al.
European Urology|December 4, 2013
Visceral disease in castration-resistant prostate cancerC Pezaro, A Omlin, D Lorente, et al.
British Journal of Cancer|October 15, 2014
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abirateroneD Lorente, A Omlin, R Ferraldeschi, et al.
British Journal of Cancer|August 10, 2013
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancerA Omlin, C J Pezaro, S Zaidi, et al.
Pageof 8